Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Has Consensus Target Price of $26.67 According to AnalystsDefense World · Oct 16, 2026
ImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial SurveyDefense World · Oct 11, 2026
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 StudyMarketBeat · Oct 6, 2026
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk TranscriptSeeking Alpha · Oct 1, 2026
Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular DiseaseBenzinga · Oct 1, 2026Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.38 | -$0.43 | Miss |
| May 7, 2026 | -$0.28 | -$0.45 | Miss |
| Mar 17, 2026 | -$0.35 | -$0.54 | Miss |
| Nov 6, 2025 | -$0.37 | -$0.33 | Beat |
| Aug 7, 2025 | -$0.38 | -$0.15 | Beat |
| May 8, 2025 | -$0.00 | $0.57 | Beat |